Boehringer Ingelheim Inks $357M Deal for Cue Biopharma’s Novel Autoimmune Bispecific CUE-501

On April 15, Boehringer Ingelheim (BI) and Cue Biopharma announced a strategic research collaboration and license agreement to jointly develop and commercialize CUE-501, a candidate product from Cue Biopharma. This therapy is a differentiated B-cell depletion treatment for autoimmune diseases.

Under the terms of the agreement, Cue Biopharma’s technology will be utilized to further research and advance the development of the candidate molecule. The parties may also expand their collaboration in the future to potentially develop additional B-cell-targeted bispecific therapeutics for a range of autoimmune diseases.

In return, Cue Biopharma is entitled to a $12 million upfront payment. Additionally, Cue Biopharma is eligible for total research and development and commercial milestone payments of approximately $345 million (including two preclinical development milestones), as well as royalties on net sales.

CUE-501 is a CD19/HLA bispecific antibody that binds to B-cell-specific membrane proteins while selectively engaging virus-specific memory cytotoxic T cells, thereby enabling the selective depletion of B cells and suppressing autoimmune and inflammatory responses.

Compared with other B-cell-targeted therapies, CUE-501 is expected to offer superior efficacy and safety, with the potential for early intervention in the course of patient treatment to achieve long-term disease control. The Insight database shows that CUE-501 is the only CD19/HLA-targeted therapy available worldwide.

The innovation of CUE-501 is underpinned by the technological support provided by Cue Biopharma’s Immuno-STAT™ platform. This proprietary platform is designed to develop a novel class of injectable biologics that can selectively engage and modulate disease-specific T cells within patients.

The core mechanism of the Immuno-STAT™ platform lies in mimicking the natural process of antigen-presenting cells (APCs). Antigen-presenting cells play a pivotal role in immune responses by activating tumor-specific cytotoxic T cells through the simultaneous presentation of two signals.

Specifically, Signal 1 involves the presentation of disease-specific proteins (such as tumor-specific antigens or self-specific antigens) via peptide–major histocompatibility complex (pMHC) molecules to the T-cell receptors of target T cells, thereby modulating the T-cell repertoire and eliciting a specific immune response. In the field of oncology, Signal 2 typically consists of key immunostimulatory signals, such as interleukin-2 (IL-2), which are used to selectively activate tumor-specific cytotoxic T cells; in the context of autoimmune diseases, Signal 2 can be replaced by immunosuppressive signals.

Daniel Passeri, CEO of Cue Biopharma, stated that the collaboration with Boehringer Ingelheim will enable further development of candidate molecules and is expected to validate the potential of the Immuno STAT™ platform as a breakthrough novel approach capable of selectively redirecting and harnessing potent antiviral memory T cells to target pathological cells.

The development of bispecific antibodies in oncology has matured, whereas their deployment in the autoimmune disease space remains relatively limited. Multinational corporations (MNCs) that first recognized this opportunity have already taken the lead.

In recent years, with the rapid advancement in the field of autoimmune diseases and the continuous emergence of new targets, pharmaceutical giants such as Johnson & Johnson, Sanofi, and Roche have expanded their product portfolios and iterated on therapies by developing bispecific antibody pipelines. In particular, bispecific antibody products targeting CD3, TSLP, and interleukin family members—targets with proven druggability—have become a focal point of new drug development at multinational corporations (MNCs).

Among them, Sanofi, Merck & Co., and Roche have chosen to stake their claim in the CD3 bispecific antibody space. CD3 is closely linked to T-cell activation; by binding to both CD3 and tumor-associated antigens, these agents can guide and activate T cells to approach and kill tumor cells. Currently, most approved bispecific antibodies globally are CD3-targeted T-cell engagers (TCEs), with indications spanning hematologic malignancies and solid tumors. Meanwhile, CD3 bispecific antibodies are also expanding into the autoimmune disease sector. Today, CD3 bispecific antibodies have become a critical new battleground for multinational corporations (MNCs) in the autoimmune field. If successfully validated in the future, CD3 bispecific antibodies could emerge as blockbuster drugs with potential across three major therapeutic markets: solid tumors, hematologic malignancies, and autoimmune diseases.

Meanwhile, Sanofi and Pfizer have positioned themselves in the TSLP bispecific antibody space. Thymic stromal lymphopoietin (TSLP) is a novel cytokine similar to IL-7, and the TSLP target has been validated as being associated with various autoimmune diseases, including atopic dermatitis, psoriasis, and rheumatoid arthritis. In 2021, Tezepelumab, jointly developed by Amgen and AstraZeneca, received marketing approval; it remains the only approved TSLP monoclonal antibody globally, indicated for the treatment of severe asthma. Following its launch, Tezepelumab’s sales rose rapidly, reaching $170 million globally in 2022 and growing to $570 million in 2023. The drug’s impressive commercial performance has attracted multiple multinational corporations (MNCs) to target TSLP, with R&D efforts primarily focused on TSLP bispecific and trispecific antibodies, many of which have entered mid-to-late stage clinical trials.

Johnson & Johnson is addressing multiple pathogenic pathways by building a differentiated and complementary portfolio of bispecific antibodies. Last May, J&J, which already held five flagship autoimmune products, acquired Proteologix for $850 million, securing its core assets PX128 and PX130. The former is an IL-13/TSLP bispecific antibody for the treatment of atopic dermatitis and asthma, currently in Phase I clinical trials; the latter is an IL-13/IL-22 bispecific antibody for the treatment of atopic dermatitis, currently in preclinical studies.

The autoimmune disease sector boasts significant market potential. According to Frost & Sullivan’s projections, the global market for autoimmune disease drugs is expected to reach $176 billion by 2030, with a compound annual growth rate (CAGR) of 3.6% from 2022 to 2030. Among this, China’s market size is projected to approach $25 billion by 2030, representing a tenfold increase compared to 2020, making it a major source of incremental growth in the global autoimmune drug market.

The autoimmune disease landscape encompasses a wide variety of conditions, affects a large patient population, and addresses substantial unmet clinical needs, thereby continuously contributing new growth potential to the pharmaceutical industry. For multinational corporations (MNCs) facing patent cliffs and growth crises, the autoimmune sector is undoubtedly a fertile ground worthy of deep cultivation.

For Boehringer Ingelheim, this collaboration with Cue Biopharma will not only bring promising bispecific antibodies for autoimmune diseases but also strengthen its R&D capabilities in the autoimmune field by leveraging Cue Biopharma’s technology platform.

Carine Boustany, Head of Boehringer Ingelheim’s U.S. Research Center and Global Head of Immunology and Respiratory Disease Research, stated: “This collaboration represents a strategic expansion of Boehringer Ingelheim’s portfolio in the field of autoimmune and inflammatory diseases. By leveraging Cue Biopharma’s proprietary T-cell engager platform, the company aims to provide more effective treatment options for patients with autoimmune conditions at earlier stages of disease.”

References:

59.1 Billion! The First Wave of Enlightened MNCs – Yaozhi.com